The Preventive and Treatment of the Neuro-Inflammasome in Sorokdo National Hospital

Abstract

Aim/Background: This study investigated leprosy patients with Alzheimer's disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor. Method: We searched all medical records of the National Health Insurance Service (NHIS) in Korea and the Sorokdo National Hospital from the time when the Korean government computerized the International Classification of Diseases (ICD)-9 code and Electronic Data Interchange (EDI). The Seoul study analyzed statistically AD, and anti-AD drugs (AADs) in the Sorokdo National Hospital's EDI database archived from January 2005 to June 2020 through the ICD-9 and -10 codes with National Health Insurance System. Result: The relation between DDS and AD each year was analysed using the chi-square test. P value was significant from 2007 to 2020 when P-value < 0.05 was considered significant. The AD (+/-) Group was rearranged based on the DDS (+/-) Group. DDS’s effect as a neuro-inflammasome competitor was statistically proved with T-Test Calculator by comparing the prevalence of AD in patients who had been prescribed DDS and those who had not. Conclusion: Our study is the first to prove the association between dapsone and AD through observational studies. This study suggests the use of neuroinflammasome therapy as a preventive and therapeutic method for AD.